Is the Time Ripe to Buy Johnson & Johnson (JNJ) Stock?

If you owned Johnson & Johnson (NYSE:JNJ) stock at the beginning of 2013, you’re sitting atop gains of more than 20% right now. If you didn’t own shares of J&J, you might be wishing that you did. Is the time still ripe to buy — or has the train left the station? Let’s take a look.

Taking a breather

After a stellar start in 2013, Johnson & Johnson (NYSE:JNJ) has taken a little breather since late May. Shares have pulled back slightly.

JNJ Chart

JNJ data by YCharts.

I actually view this as a good development. The S&P 500 index also pulled back during the same period, but Johnson & Johnson (NYSE:JNJ) shares retreated by less than half as much as the broader index. This reflects solid investor support for the stock.

It’s been a while since J&J enjoyed such a nice run. The company has encountered some rough spots over the last few years, particularly with product recalls and litigation woes. These issues even resulted in Warren Buffett dumping much of his stake, saying that Johnson & Johnson (NYSE:JNJ) had made “too many mistakes.”

Johnson & Johnson (NYSE:JNJ)

Relatively speaking

Of course, J&J hasn’t been alone in climbing this year. Many blue chips have performed well in 2013 thus far. Among its peers, though, Johnson & Johnson (NYSE:JNJ) stock looks to be one of the biggest winners.

Fellow pharmaceutical giant Pfizer Inc. (NYSE:PFE) saw its shares jump more than 20% by April. However, the stock has fallen quite a bit since then. Shares are now only up less than 13%.

Similarly, Merck & Co., Inc. (NYSE:MRK) was up more than 20% for the year in early June. The stock now claims year-to-date gains of 14%.

Although its quite smaller in terms of market cap, Abbott Laboratories (NYSE:ABT) has a business model closer to that of Johnson & Johnson than most other pharmaceutical firms. Abbott shares followed a similar path as Merck & Co., Inc. (NYSE:MRK) — up more than 20% before falling. The stock is now up around 14% for the year.

Since J&J didn’t pull back as much as some of its peers, is it now much pricier as a result? Not necessarily.

Its trailing price-to-earnings multiple of below 24 stands very close to that of Merck. Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) have significantly lower trailing P/E values of less than 14 and 11, respectively. However, looking ahead paints a different picture.

Abbott’s forward P/E of almost 16 ranks as the highest of the four companies. J&J trails with a forward P/E a little under 15. Meanwhile, Pfizer and Merck both have forward multiples between 12 and 13. Factoring in these expectations of future earnings makes Johnson & Johnson stock look reasonably priced in comparison with the other stocks.

Wonderful

For investors looking at the long run, Johnson & Johnson is nearly always worth consideration. Just as Warren Buffett said when discussing the company’s mistakes in recent years, J&J has “a lot of wonderful products and it’s got a wonderful balance sheet.”

I’d throw in a wonderful dividend yield to that mix. J&J’s yield currently stands at 3.2%. Is the time ripe to buy Johnson & Johnson stock? The signs point to it being a wonderful time.

The article Is the Time Ripe to Buy Johnson & Johnson Stock? originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

The 50 Best Personal Finance Blogs

Most Expensive Apartments in New York City

Bloodiest UFC Fights Ever Fought

Most Expensive Rum Brands in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!